← Oncology Approval Tracker

FDA DECISION ·

Tecvayli + Darzalex Faspro

teclistamab-cqyv with daratumumab and hyaluronidase-fihj · Janssen Biotech

FDA approvalNew or expanded indicationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory multiple myeloma after at least one prior line containing a proteasome inhibitor and an immunomodulatory drug.

SUPPORTING DATA

Evidence behind the decision

Study
MajesTEC-3 randomized 587 patients to teclistamab plus subcutaneous daratumumab or investigator choice of two active daratumumab regimens.
Key result
Median progression-free survival was unreached versus 18.1 months (hazard ratio 0.17, 95% CI, 0.12–0.23).
Safety to report
FDA describes boxed warnings for cytokine release syndrome and neurologic toxicity. Review the current REMS and infection precautions.
Evidence limits
The result compares the combination with DPd or DVd. It cannot be attributed to teclistamab monotherapy in a different treatment line.

LAMPGEN ANALYSIS

Why it matters

The approval moves a BCMA-directed bispecific combination into earlier relapsed disease. MajesTEC-3 evaluated the combination against active daratumumab regimens.

What research teams should watch

Sites need step-up dosing readiness, CRS and neurologic toxicity escalation, infection surveillance and familiarity with the current REMS requirements.

Clinical operations takeaway

Ask monitors to describe how they would verify site readiness, document safety follow-up, and escalate an unresolved finding under the study plan. Make those responsibilities part of the monitoring brief.

Explore oncology CRA staffing

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

Relapsed or refractory multiple myeloma

PRIMARY RECORDS

Sources